Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

GlycoMimetics, Inc. GLYC NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

GlycoMimetics, Inc. (GLYC) is a Biotechnology company in the Healthcare sector, currently trading at $15.71. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $150M (loss), growing at -79.3%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+1377.6 pp trend).

Balance sheet: total debt is $2M against $203M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 6.56 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $240M.

Analyst outlook: 8 / 13 analysts rate GLYC as buy (62%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 55/100 (Partial), Income ?/100 (Fail).

GLYC SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GLYC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
GLYC: -93.3%/yr revenue is, -79.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet GLYC: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 6.56 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
GLYC: Gross margin is 100% (+1377.6 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 8 / 13 analysts rate GLYC as buy (62%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.153-63
Volume612
Avg Volume (30D)19.73K
Market Cap$1.01B
Beta (1Y)1.60
Share Statistics
EPS (TTM)-12,818.00
Shares Outstanding$104.14M
IPO Date2014-01-10
Employees4
CEOStephanie R. Irish CPA
Financial Highlights & Ratios
EBITDA$-149.67M
Net Income$-149.94M
Operating Income$-152.63M
Total Cash$213.19M
Total Debt$1.64M
Net Debt$-211.55M
Total Assets$240.29M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering13
Buy 62% Hold 38% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS38000Q2012

Price Chart

Track all markets on TradingView
GLYC
GlycoMimetics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.15 52WK RANGE 63.00

People Also View

DYN
DYN
Dyne Therapeutics, Inc.
$19.81
+4.26%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 TRVI
TRVI
Trevi Therapeutics, Inc.
$14.04
+5.33%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 IVA
IVA
Inventiva S.A.
$5.51
+9.98%
 FHTX
FHTX
Foghorn Therapeutics Inc.
$4.85
+3.41%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message